Osteoarthritis in Europe | Pfizer & The Economist
Post# of 7791
(Total Views: 263)
Posted On: 04/13/2023 12:32:15 AM
Osteoarthritis in Europe | Pfizer & The Economist Intelligence Unit
Osteoarthritis (OA) is a chronic joint condition, which causes pain, stiffness and mobility problems. The number of people affected in Western Europe has grown 54% in the past 30 years, reaching 57 million in 2019 and causing 2 million years lived with disability.
In this report, the Economist Intelligence Unit looks at the costs of failing to meet the needs of people with OA. We examine the burden of the disease on patients, on caregivers and on wider societies and economies, drawing on the latest research and data.
"We focus on OA in six European countries:
France, Germany, Italy, Spain, Sweden and the UK. The report highlights current treatment best practices, as recommended by national, European and international guidelines. Through in-depth interviews with healthcare professionals and patient representatives, we consider the barriers to implementation of the best care and explore the reasons why patients’ needs still go unmet."
https://osteoarthritisineurope.eiu.com/
Reading this type of material, makes it very clear that Biel products are needed in the world like the air we breathe. There is a lot of work to be done. We are just beginning to scratch the surface. Why?
Because we have partners in Italy, Spain, Sweden and the UK (among other European countries) that have their work cut out for them.
We haven't reached critical mass yet.
When we do, we will instantly know it, lol.
Go Biel
Osteoarthritis (OA) is a chronic joint condition, which causes pain, stiffness and mobility problems. The number of people affected in Western Europe has grown 54% in the past 30 years, reaching 57 million in 2019 and causing 2 million years lived with disability.
In this report, the Economist Intelligence Unit looks at the costs of failing to meet the needs of people with OA. We examine the burden of the disease on patients, on caregivers and on wider societies and economies, drawing on the latest research and data.
"We focus on OA in six European countries:
France, Germany, Italy, Spain, Sweden and the UK. The report highlights current treatment best practices, as recommended by national, European and international guidelines. Through in-depth interviews with healthcare professionals and patient representatives, we consider the barriers to implementation of the best care and explore the reasons why patients’ needs still go unmet."
https://osteoarthritisineurope.eiu.com/
Reading this type of material, makes it very clear that Biel products are needed in the world like the air we breathe. There is a lot of work to be done. We are just beginning to scratch the surface. Why?
Because we have partners in Italy, Spain, Sweden and the UK (among other European countries) that have their work cut out for them.
We haven't reached critical mass yet.
When we do, we will instantly know it, lol.
Go Biel
(0)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼